BioSpace News Archive

Sun Pharmaceutical Industries Ltd. (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715, “Sun Pharma” including its subsidiaries and/or associate companies) today announced that one of its wholly owned subsidiaries presented long-term follow-up data from ILUMYA® (tildrakizumab-asmn) Phase 3 reSURFACE 1 and 2 trials at the 28th European Academy of Dermatology and Venereology Congress (EADV) in Madrid, Spain.

The 2019 National Electrical Contractors Association (NECA) Convention & Trade Show in Las Vegas drew its highest purchasing power to date.

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, announced today that its products will be included in various presentations at the American Academy of Ophthalmology (AAO) annual meeting, which begins Saturday, October 12, 2019

Centene Corporation (NYSE: CNC) announced today that Edmund Kroll, Senior Vice President, Finance & Investor Relations, has advised the company of his intention to retire, effective April 30, 2020.

Community Healthcare Trust Incorporated (NYSE: CHCT) today announced that on Tuesday evening, November 5, 2019, after the market closes, it will report results for the third quarter of 2019.

Approval follows multi-center investigational clinical trial evaluating safety and efficacy of TSolution One® Total Knee Application

At the European Academy of Dermatology and Venereology annual meeting 10-12 October, in Madrid, Spain, Canfield Scientific will showcase several new, innovative AI-driven dermatology solutions along with significant enhancements to their aesthetic solutions.

FIRE-UP PD study supports community engagement projects led by academic centers in Boston, Chicago, Denver and Southern Florida

Research shows errors that occur in the pre-analytical phase of testing may contribute up to 75% of erroneous test results, with 26% possibly having an adverse effect on patient care.

Hart, who joined George Clinical through the acquisition of Vector Oncology in 2017, will now lead business development functions globally for the organization.